<DOC>
	<DOC>NCT00179855</DOC>
	<brief_summary>The purpose of this research study is to evaluate the safety and feasibility of extracorporeal photopheresis (ECP) in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in children.</brief_summary>
	<brief_title>Extracorporeal Photopheresis for Acute Graft Versus Host Disease</brief_title>
	<detailed_description />
	<mesh_term>Graft vs Host Disease</mesh_term>
	<criteria>Statuspost allogeneic stem cell transplant (includes cord blood transplant, matchedunrelateddonor transplant and matchedrelated donor transplant) for any indication. HLA matching needs to be 46/6 by at least intermediate resolution for class I + II for cord blood and 56/6 for matched related or matched unrelated donors. Diagnosis of grade IIIV acute GVHD with histological confirmation of at least one organ (skin, gut, or liver) within the last 14 days. Grading of acute GVHD is per the standard Keystone criteria. Prior to enrollment, efforts should be made to rule out diagnoses that may mimic GVHD, such as drug rashes or GI infection. Patients that are being treated for acute GVHD and appear to be progressing to chronic GVHD are also eligible No improvement, or worsening, of acute GVHD after at least 4 days of IV methylprednisolone dosed at, at least 2.0mg/kg/day.. Weight &gt;25.0kg. Adequate venous access. Evidence of venoocclusive disease. Intubated patient. Patient receiving dialysis. Age &gt; 30. Total bilirubin &gt;15mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>ECP</keyword>
	<keyword>extracorporeal photopheresis</keyword>
	<keyword>allogeneic transplantation</keyword>
</DOC>